Lowest-Rated StocksLowest-RatedNASDAQ:DOCS Doximity (DOCS) Stock Price, News & Analysis → Bible Shocker: Have You Seen Elon Musk’s Miracle? (From InvestorPlace) (Ad) Free DOCS Stock Alerts $28.03 +4.29 (+18.07%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$26.21▼$29.0050-Day Range$23.00▼$28.5052-Week Range$19.71▼$36.29Volume9.98 million shsAverage Volume1.53 million shsMarket Capitalization$5.23 billionP/E Ratio38.93Dividend YieldN/APrice Target$28.73 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial Media Get Doximity alerts: Email Address Doximity MarketRank™ Stock AnalysisAnalyst RatingHold2.13 Rating ScoreUpside/Downside2.5% Upside$28.73 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment0.50Based on 43 Articles This WeekInsider TradingSelling Shares$171,250 Sold Last QuarterProj. Earnings Growth11.69%From $0.77 to $0.86 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.96 out of 5 starsMedical Sector486th out of 922 stocksCustom Computer Programming Services Industry13th out of 24 stocks 2.1 Analyst's Opinion Consensus RatingDoximity has received a consensus rating of Hold. The company's average rating score is 2.13, and is based on 3 buy ratings, 11 hold ratings, and 1 sell rating.Amount of Analyst CoverageDoximity has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Doximity's stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for DOCS. Previous Next 0.0 Dividend Strength Dividend YieldDoximity does not currently pay a dividend.Dividend GrowthDoximity does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DOCS. Previous Next 3.1 News and Social Media Coverage News SentimentDoximity has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 43 news articles for Doximity this week, compared to 5 articles on an average week.Search Interest26 people have searched for DOCS on MarketBeat in the last 30 days. This is an increase of 333% compared to the previous 30 days.MarketBeat Follows10 people have added Doximity to their MarketBeat watchlist in the last 30 days. This is an increase of 43% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Doximity insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $171,250.00 in company stock.Percentage Held by Insiders39.40% of the stock of Doximity is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions87.19% of the stock of Doximity is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Doximity's insider trading history. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Doximity are expected to grow by 11.69% in the coming year, from $0.77 to $0.86 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Doximity is 38.93, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 130.05.Price to Earnings Ratio vs. SectorThe P/E ratio of Doximity is 38.93, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 137.80.Price to Earnings Growth RatioDoximity has a PEG Ratio of 2.99. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioDoximity has a P/B Ratio of 5.63. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Doximity's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceMan who spotted Apple at $1.49 says: “Buy These 6 AI Stocks.”Man who spotted Apple at $1.49 says: "Buy These 6 AI Stocks."And these will be the biggest winners About Doximity Stock (NASDAQ:DOCS)Doximity, Inc. operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers. It primarily serves pharmaceutical manufacturers and healthcare systems. The company was formerly known as 3MD Communications, Inc. and changed its name to Doximity, Inc. in June 2010. Doximity, Inc. was incorporated in 2010 and is headquartered in San Francisco, California.Read More DOCS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DOCS Stock News HeadlinesMay 18 at 10:41 AM | insidertrades.comDoximity, Inc. (NASDAQ:DOCS) Insider Craig Overpeck Sells 1,500 SharesMay 19 at 6:02 AM | americanbankingnews.comDoximity (NASDAQ:DOCS) PT Raised to $29.00May 19 at 6:02 AM | americanbankingnews.comNeedham & Company LLC Reiterates Hold Rating for Doximity (NASDAQ:DOCS)May 19 at 2:30 AM | americanbankingnews.comDoximity (NASDAQ:DOCS) Rating Reiterated by William BlairMay 18 at 3:42 AM | americanbankingnews.comDoximity Target of Unusually High Options Trading (NASDAQ:DOCS)May 18 at 2:18 AM | americanbankingnews.comDoximity (NASDAQ:DOCS) Shares Gap Up Following Analyst UpgradeMay 17 at 10:45 PM | prnewswire.comDOXIMITY SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Doximity, Inc. - DOCSMay 17 at 1:10 PM | investopedia.comDoximity Surges on Earnings Beat, Strong Outlook, Stock Buyback AnnouncementMay 17 at 12:13 PM | markets.businessinsider.comDoximity’s Strong Q4 Performance and Positive Outlook Justify Buy RatingMay 17 at 12:13 PM | markets.businessinsider.comDoximity (DOCS) Hold Rating Maintained Amid Balanced Growth Prospects and Market UncertaintyMay 17 at 12:13 PM | msn.comDOCS Earnings: Doximity Stock Gains on Impressive Q4 ReportMay 17 at 12:13 PM | msn.comDoximity, Inc. (NYSE:DOCS) Q4 2024 Earnings Call TranscriptMay 17 at 12:13 PM | theglobeandmail.comDoximity (DOCS) Stock Trades Up, Here Is WhyMay 17 at 11:15 AM | fool.comWhy Doximity Stock Is Skyrocketing TodayMay 17 at 7:12 AM | seekingalpha.comDoximity Earnings: Better Than Expected, But Still Mixed Outlook (Rating Upgrade)May 16 at 9:11 PM | markets.businessinsider.comROSEN, TRUSTED INVESTOR COUNSEL, Encourages Doximity, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - DOCSMay 16 at 9:11 PM | theglobeandmail.comDoximity's (NYSE:DOCS) Q1 Sales Top Estimates, Full-Year Guidance RaisedMay 16 at 9:11 PM | msn.comDoximity Stock Jumps 10% On Q4 Earnings: What You Need To KnowMay 16 at 4:45 PM | prnewswire.comDOCS Investors Have Opportunity to Lead Doximity, Inc. Securities Fraud LawsuitMay 16 at 4:10 PM | finance.yahoo.comDoximity Announces Fourth Quarter and Fiscal Year 2024 Financial ResultsMay 16 at 4:01 PM | businesswire.comDoximity Announces Fourth Quarter and Fiscal Year 2024 Financial ResultsMay 16 at 1:58 AM | americanbankingnews.comDoximity, Inc. (NASDAQ:DOCS) Receives Average Rating of "Hold" from AnalystsMay 15, 2024 | prnewswire.comROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Doximity, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - DOCSMay 15, 2024 | prnewswire.comDoximity, Inc. (DOCS) Investors: June 17, 2024 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLPMay 15, 2024 | businesswire.comKirby McInerney LLP Reminds Doximity, Inc. (DOCS) Investors of Class Action Filing and Encourages Investors to Contact the FirmSee More Headlines Receive DOCS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Doximity and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2021Today5/18/2024Next Earnings (Estimated)8/13/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Custom computer programming services Sub-IndustryN/A Current SymbolNASDAQ:DOCS CUSIPN/A CIK1516513 Webwww.doximity.com Phone650-549-4330FaxN/AEmployees977Year FoundedN/APrice Target and Rating Average Stock Price Target$28.73 High Stock Price Target$33.00 Low Stock Price Target$23.00 Potential Upside/Downside+2.5%Consensus RatingHold Rating Score (0-4)2.13 Research Coverage15 Analysts Profitability EPS (Most Recent Fiscal Year)$0.72 Trailing P/E Ratio38.93 Forward P/E Ratio36.40 P/E Growth2.99Net Income$112.82 million Net Margins31.04% Pretax Margin37.15% Return on Equity17.40% Return on Assets14.92% Debt Debt-to-Equity RatioN/A Current Ratio8.03 Quick Ratio8.03 Sales & Book Value Annual Sales$475.42 million Price / Sales11.00 Cash Flow$0.85 per share Price / Cash Flow33.05 Book Value$4.98 per share Price / Book5.63Miscellaneous Outstanding Shares186,550,000Free Float113,052,000Market Cap$5.23 billion OptionableNot Optionable Beta1.18 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Jeffrey A. Tangney (Age 51)Co-Founder, CEO & Chairperson Comp: $243.73kDr. Nate Gross M.D. (Age 40)Co-Founder & Chief Strategy Officer Comp: $455.54kMs. Anna Bryson (Age 34)Chief Financial Officer Comp: $453.71kMs. Jennifer W. Chaloemtiarana (Age 56)General Counsel & Corporate Secretary Comp: $504.04kMr. Paul Jorgensen (Age 53)Chief Revenue Officer Comp: $455.13kMs. Shari BuckCo-founder and SVP People & OpsMr. Jey BalachandranChief Technology OfficerMr. Perry Scott GoldHead of Investor RelationsJim RivasHead of Corporate CommunicationsMr. Bruno MirandaSenior VP of EngineeringMore ExecutivesKey CompetitorsTransMedics GroupNASDAQ:TMDXNuvalentNASDAQ:NUVLImmunovantNASDAQ:IMVTSelect MedicalNYSE:SEMAlpine Immune SciencesNASDAQ:ALPNView All CompetitorsInsiders & InstitutionsComerica BankBought 2,480 shares on 5/17/2024Ownership: 0.034%iA Global Asset Management Inc.Bought 7,208 shares on 5/17/2024Ownership: 0.018%Walleye Trading LLCSold 12,100 shares on 5/17/2024Ownership: 0.000%Kira Scherer WamplerSold 2,500 sharesTotal: $68,050.00 ($27.22/share)California State Teachers Retirement SystemSold 11,698 shares on 5/16/2024Ownership: 0.059%View All Insider TransactionsView All Institutional Transactions DOCS Stock Analysis - Frequently Asked Questions Should I buy or sell Doximity stock right now? 15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Doximity in the last year. There are currently 1 sell rating, 11 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" DOCS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DOCS, but not buy additional shares or sell existing shares. View DOCS analyst ratings or view top-rated stocks. What is Doximity's stock price target for 2024? 15 Wall Street analysts have issued 12-month price objectives for Doximity's stock. Their DOCS share price targets range from $23.00 to $33.00. On average, they anticipate the company's stock price to reach $28.73 in the next year. This suggests a possible upside of 2.5% from the stock's current price. View analysts price targets for DOCS or view top-rated stocks among Wall Street analysts. How have DOCS shares performed in 2024? Doximity's stock was trading at $28.04 at the start of the year. Since then, DOCS stock has decreased by 0.0% and is now trading at $28.03. View the best growth stocks for 2024 here. When is Doximity's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our DOCS earnings forecast. How were Doximity's earnings last quarter? Doximity, Inc. (NASDAQ:DOCS) released its quarterly earnings results on Tuesday, November, 9th. The company reported $0.19 EPS for the quarter, beating the consensus estimate of $0.06 by $0.13. The business had revenue of $79.35 million for the quarter, compared to the consensus estimate of $73.60 million. Doximity had a net margin of 31.04% and a trailing twelve-month return on equity of 17.40%. What ETFs hold Doximity's stock? ETFs with the largest weight of Doximity (NASDAQ:DOCS) stock in their portfolio include Global X Telemedicine & Digital Health ETF (EDOC), Jacob Forward ETF (JFWD), Janus Henderson Small Cap Growth Alpha ETF (JSML), Fidelity Digital Health ETF (FDHT), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Renaissance IPO ETF (IPO), Pacer US Large Cap Cash Cows Growth Leaders ETF (COWG) and Natixis U.S. Equity Opportunities ETF (EQOP). What guidance has Doximity issued on next quarter's earnings? Doximity updated its first quarter 2025 earnings guidance on Thursday, May, 16th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $119.5 million-$120.5 million, compared to the consensus revenue estimate of $119.2 million. When did Doximity IPO? Doximity (DOCS) raised $501 million in an initial public offering (IPO) on Thursday, June 24th 2021. The company issued 23,300,000 shares at a price of $20.00-$23.00 per share. Morgan Stanley, Goldman Sachs and J.P. Morgan Securities served as the underwriters for the IPO and Piper Sandler, William Blair, Canaccord and Raymond James were co-managers. Who are Doximity's major shareholders? Doximity's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (5.77%), Baillie Gifford & Co. (3.33%), William Blair Investment Management LLC (2.96%), Clearbridge Investments LLC (2.93%), Janus Henderson Group PLC (1.33%) and Edmond DE Rothschild Holding S.A. (1.06%). Insiders that own company stock include Anna Bryson, Craig Overpeck, Gilbert H Kliman, Interwest Partners X Lp, Joseph B Kleine, Kevin Spain, Kira Scherer Wampler, Paul W Jorgensen and Timothy S Cabral. View institutional ownership trends. How do I buy shares of Doximity? Shares of DOCS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:DOCS) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersBuy this small stock before coming AI Tidal WaveChaikin AnalyticsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingDems have chosen Biden replacement?Paradigm PressForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersA letter is coming from the "Bureau of the Fiscal Service".Stansberry ResearchHow Biden has already won 2024Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Doximity, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.